During primary CDI, IL-33 treatment led to an increase of ILC2s and a decrease in ILC1 and ILC3 populations in the mesenteric lymph nodes (MLN) (Figure 5, A–D) and colon (Supplemental Figure 6, A–D). The gene discussed is IL33; the disease is clostridium difficile infection.